Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCERA: dosing frequency of continuous erythropoietin receptor activator in hemodialysis patients with renal anemia
jRCTs031180030Completed
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised trial of methoxy polyethylene glycol-epoetin beta in anaemia and anemia of renal disease (2 arms). Primary endpoint: CERA dose over 12-week comparison period. Started Feb 2019; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anaemiaanemia of renal disease
Beyond the preview
Go deeper on jRCTs031180030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180030.